FERRISI, REBECCA
FERRISI, REBECCA
Dipartimento di Scienze Farmaceutiche
Novel Orthosteric/Allosteric Ligands of Cannabinoid Receptors: An Unexpected Pharmacological Profile
2025 R. Ferrisi, B. Polini, A.M. Smolyakova, C. Migone, G. Giammattei, M. Banti, G. Baron, L. Della Vedova, G. Chiellini, F. Gado, A.M. Piras, S. Rapposelli, R.B. Laprairie, G. Ortore, C. Manera
A Proteomic Approach Identified TFEB as a Key Player in the Protective Action of Novel CB2R Bitopic Ligand FD22a against the Deleterious Effects Induced by β-Amyloid in Glial Cells
2024 B. Polini, L. Zallocco, F. Gado, R. Ferrisi, C. Ricardi, M. Zuccarini, V. Carnicelli, C. Manera, M. Ronci, A. Lucacchini, R. Zucchi, L. Giusti, G. Chiellini
Dual Cannabinoid and Orexin Regulation of Anhedonic Behaviour Caused by Prolonged Restraint Stress
2023 H.J.J. Kim, A. Zagzoog, C. Ceni, R. Ferrisi, N. Janz, R.B. Laprairie
The interplay between cannabinoid receptors and microglia in the pathophysiology of Alzheimer's disease
2023 R. Ferrisi, F. Gado, C. Ricardi, B. Polini, C. Manera, G. Chiellini
New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2
2023 R. Ferrisi, B. Polini, C. Ricardi, F. Gado, K.A. Mohamed, G. Baron, S. Faiella, G. Poli, S. Rapposelli, G. Saccomanni, G. Aldini, G. Chiellini, R.B. Laprairie, C. Manera, G. Ortore
Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R)
2022 R. Ferrisi, F. Gado, B. Polini, C. Ricardi, K.A. Mohamed, L.A. Stevenson, G. Ortore, S. Rapposelli, G. Saccomanni, R.G. Pertwee, R.B. Laprairie, C. Manera, G. Chiellini
Synthesis and In Vitro Characterization of Selective Cannabinoid {CB}2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells
2022 F. Gado, R. Ferrisi, S. Di Somma, F. Napolitano, K.A. Mohamed, L.A. Stevenson, S. Rapposelli, G. Saccomanni, G. Portella, R.G. Pertwee, R.B. Laprairie, A. Maria Malfitano, C. Manera
Design, Synthesis, and Biological Activity of New {CB}2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands
2022 F. Gado, R. Ferrisi, B. Polini, K.A. Mohamed, C. Ricardi, E. Lucarini, S. Carpi, F. Domenichini, L.A. Stevenson, S. Rapposelli, G. Saccomanni, P. Nieri, G. Ortore, R.G. Pertwee, C. Ghelardini, L. Di Cesare Mannelli, G. Chiellini, R.B. Laprairie, C. Manera
CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators
2022 F. Gado, C. Ceni, R. Ferrisi, G. Sbrana, L.A. Stevenson, M. Macchia, R.G. Pertwee, S. Bertini, C. Manera, G. Ortore
The role of cannabinoids in bone metabolism: A new perspective for bone disorders
2021 F. Saponaro, R. Ferrisi, F. Gado, B. Polini, A. Saba, C. Manera, G. Chiellini
Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase ({MAGL}) inhibitors
2021 C. Granchi, G. Bononi, R. Ferrisi, E. Gori, G. Mantini, S. Glasmacher, G. Poli, S. Palazzolo, I. Caligiuri, F. Rizzolio, V. Canzonieri, T. Perin, J. Gertsch, A. Sodi, E. Giovannetti, M. Macchia, F. Minutolo, T. Tuccinardi, A. Chicca
Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases
2021 R. Ferrisi, C. Ceni, S. Bertini, M. Macchia, C. Manera, F. Gado
Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor
2021 F. Gado, K.A. Mohamed, S. Meini, R. Ferrisi, S. Bertini, M. Digiacomo, F. D'Andrea, L.A. Stevenson, R.B. Laprairie, R.G. Pertwee, C. Manera
Positive allosteric modulation of CB1 and CB2 cannabinoid receptors enhances the neuroprotective activity of a dual CB1R/CB2R orthosteric agonist
2020 B. Polini, C. Cervetto, S. Carpi, S. Pelassa, F. Gado, R. Ferrisi, S. Bertini, P. Nieri, M. Marcoli, C. Manera